Genome Editing and Engineering
From TALENs, ZFNs and CRISPRs to Molecular Surgery

A complete guide to endonuclease-based genomic engineering, from basic science to application in disease biology and clinical treatment.

Krishnarao Appasani (Edited by), George M. Church (Foreword by)

9781107170377, Cambridge University Press

Hardback, published 23 August 2018

498 pages, 122 b/w illus. 32 colour illus. 9 tables
25.2 x 17.7 x 3 cm, 1.19 kg

'… providing significant and useful information on current knowledge in the field and promoting the interaction between basic and pre-clinical/clinical research … of potential interest to a broad readership interested in basic and translational research.' Antonio Russo, 'P. Giaccone' University Hospital, University of Palermo, Italy

Recent advances in genome editing tools using endonucleases such as TALENs, ZFNs, and CRISPRs, combined with genomic engineering technologies, have opened up a wide range of opportunities from applications in the basic sciences and disease biology research, to the potential for clinical applications and the development of new diagnostic tools. This complete guide to endonuclease-based genomic engineering gives readers a thorough understanding of this rapidly expanding field. Chapters cover the discovery, basic science, and application of these techniques, focusing particularly on their potential relevance to the treatment of cancer, and cardiovascular and immunological disease. The final section discusses the legal and ethical issues which accompany the technology. Providing authoritative coverage of the potential that genome editing and engineering have, this is an ideal reference for researchers and graduate students and those working in the biotechnology and pharmaceutical industries, as well as in a clinical setting.

List of contributors
Forewords
Preface
List of abbreviations
Part I. Biology of Endonucleases (Zinc-Finger Nuclease, TALENs and CRISPRs) and Regulatory Networks: 1. Introduction to genome editing and engineering: from Talens, ZFNs and CRISPRs to molecular surgery
2. Targeted genome editing techniques in C. elegans and other nematode species
3. Unbiased detection of off-target cleavage by CRISPR-Cas9 and TALENs using integrase-defective lentiviral vectors
4. In vivo studies of miRNA target interactions using site-specific genome engineering
5. Don't kill the messenger: employing genome editing to study regulatory RNA interactions
Part II. Genome Editing in Model Organisms: 6. Genome editing in the crustacean Daphnia magna using CRISPR/Cas and TALEN systems
7. Leapfrogging: a method for targeting genome editing to the germline
8. Genome editing with desired mutations (knock-in) by CRISPR in model organisms
9. Genetically engineered pig models for human diseases using ZFNs, TALENs and CRISPR-Cas9
10. Gene editing to create agricultural and biomedical swine models
11. Generation of new model cell lines using ssODN knock-in donors and FACS-based genome editing
Part III. Technology Development and Screening: 12. CRISPR genome editing in mice
13. Detection of insertion/deletion (indel) events after genome targeting: pros and cons of the available methods
14. Application of TAL proteins and the CRISPR system to purification of specific genomic regions for locus-specific identification of chromatin-associated molecules
15. Application of CRISPR for pooled, vector-based functional genomic screening in mammalian cell lines
16. Generation and utilization of CRISPR/Cas9 screening libraries in mammalian cells
Part IV. Genome Editing in Stem Cells and Regenerative Biology: 17. Targeted genome editing using nuclease assisted vector integration
18. Genome engineering using Sleeping Beauty transposition in vertebrates
19. Genome editing of pluripotent stem cells
20. Principles for targeting adult tissue stem cells to achieve durable gene and gene-editing therapies
21. Therapeutic genome editing in human hematopoietic stem and progenitor cells
Part V. Genome Editing in Disease Biology: 22. CRISPR/Cas9-Based in vivo models of cancer
23. Inducible CRISPR-based genome editing for the characterization of cancer genes
24. Genome editing for retinal diseases
25. Manipulation of long non-coding RNAs in cardiovascular disease using genome-editing technology
26. Gene silencing, disruption and latency reactivation with RNA-based and gene editing CRISPR/Cas, ZFN and TALEN technologies for HIV-1/AIDS therapies
27. Use of the CRISPR-Cas9 system for genome editing of immune system cells, defense against HIV-1 and cancer therapies
28. Harnessing therapeutic potential of long non-coding RNAs in immunity
Part VI. Legal (Intelluctual Property) and Bioethical Issues of Genome Editing: 29. Patening of CRISPR-based inventions
30. Patent, ownership, and licensing issues of CRISPR-based genome editing: impact on universities and their licensees
31. The ethics of human genome editing
32. Regulating human genome editing: negotiating ethical concerns through science and policy
Index.

Subject Areas: Genetics [non-medical PSAK], Life sciences: general issues [PSA], Biology, life sciences [PS]